Among the selected candidates, MUC4 was significantly up-regulated in both primary and metastatic samples of fast-progressing patients, whereas HTRA2 and RAB25 were significantly elevated only in primary samples and EPCAM only in metastatic tumors of the fast-progressing group. This evidence concerns the gene HTRA2 and metastatic neoplasm.